2020 29 September 2020 – Regeneus receives $676k in R&D Tax Incentives11 September 2020 – Notice of initial substantial holder – AGC Inc.11 September 2020 – Virtual Annual General Meeting Online Guide11 September 2020 – Notice of Annual General Meeting / Proxy / Question Form10 September 2020 – Issue of AGC shares complete10 September 2020 – Appendix 2A10 September 2020 – Cleansing Notice8 September 2020 – Notice of initial substantial holder – Kirman 2 Pty Ltd3 September 2020 – CEO bonus payment3 September 2020 – Appendix 3Y – Leo Lee3 September 2020 – Appendix 3G28 August 2020 – Regeneus receives milestone payment from Kyocera28 August 2020 – Appendix 4G and Corporate Governance Statement28 August 2020 – Appendix 4E and Annual Report25 August 2020 – Regeneus to present at FNN Virtual Investor Event25 August 2020 – Regeneus to be granted new Sygenus patent in US13 August 2020 – Regeneus and Kyocera sign Progenza OA deal31 July 2020 – Directors provide $4M loan to support commercial license discussions31 July 2020 – Appendix 4D and Half-Year Report31 July 2020 – Progenza OA licence with Kyocera enters final negotiation phase31 July 2020 – Regeneus signs MOU agreement with Kyocera on exclusive negotiation rights for Progenza in Japan31 July 2020 – Half-Year Results & Business Update31 July 2020 – Appendix 4C – Quarterly (Updated)31 July 2020 – 200604 – Director Resignation31 July 2020 – 200604 – Appendix 3Z – Final Director’s Interest Notice31 July 2020 – 200518 – Kyocera completes Progenza Due Diligence31 July 2020 – 200401 – Appendix 3G31 July 2020 – 200331 – Quarterly Cashflow report – Period ending31 July 2020 – 200323 – Regeneus to be granted new key Progenza patent in U.S.31 July 2020 – 200320 – RGS ann31 July 2020 – 200206 – ASX Response Letter & 3Y’s _ASX31 July 2020 – 200206 – 87585790_1_Appendix_03G (Dentons) (3)31 July 2020 – 200116 – Appendix_03G31 July 2020 – 200116 – Appendix_03G 2 2019 31 July 2020 – Rights-Issue-Investor-Presentation31 July 2020 – Rights-Issue-Investor-Presentation 031 July 2020 – Rights Issue Shortfall31 July 2020 – RGS tax credit release ASX31 July 2020 – Response To Appendix 4C 031 July 2020 – Regeneus-Trading Halt31 July 2020 – Regeneus New CEO31 July 2020 – pressRelease RGS NewInternationalDirectors31 July 2020 – Positive preclinical trial results for Progenza31 July 2020 – Notice-to-shareholders020831 July 2020 – Notice-to-option-holders31 July 2020 – New Strategy To Deliver Therapies For Global Pain Market31 July 2020 – Material Terms of Contract31 July 2020 – Form 603 – Notice of substantial holder – Leo Lee31 July 2020 – Entitlement-offer31 July 2020 – Date of AGM31 July 2020 – Confirmation of Despatch of Offer Booklet31 July 2020 – cleansing-notice31 July 2020 – Clarification to announcement31 July 2020 – Change of interests of substantial holder – Graham Vesey31 July 2020 – CEO Presentation for ASX 3.15pm31 July 2020 – Capital Raise31 July 2020 – Appendix 4E Website31 July 2020 – Appendix 3Z – Final Director Interest Notice 031 July 2020 – Appendix 3Y – Leo Lee31 July 2020 – Appendix 3Y – Glen Richards31 July 2020 – Appendix 3X – Initial Director Interest Notice 031 July 2020 – Appendix 3B31 July 2020 – Appendix 3B and Cleansing Statement31 July 2020 – Appendix 3B 031 July 2020 – 191220 – Appendix 3B AGC31 July 2020 – 191220 – AGC Termination of Agreement paves way for commercial partner31 July 2020 – 191218 – RGS government grant release ASX31 July 2020 – 191121 – Results of the Meeting 031 July 2020 – 191121 – Chairman’s Address ASX31 July 2020 – 191120 – Cleansing Statement31 July 2020 – 191120 – 86738355 1 Appendix 3B31 July 2020 – 191118 – RGS shortfall Final for ASX31 July 2020 – 191031 – Appendix 4C Query and Response31 July 2020 – 191031 – Appendix 4C ASX31 July 2020 – 191030 – App 4G & Corp Gov Statement31 July 2020 – 191030 – Annual Report ASX31 July 2020 – 191018 – NoM and Proxy for ASX31 July 2020 – 191015 – Change of Address 131 July 2020 – 190813 – ASX Release Restructuring ASX31 July 2020 – 2.5MFund See the full archive Subscribe to our investor newsletterSubscribe to Regeneus' investor newsletter for the latest information and updates Your first Name Your email Subscribe
